MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ
4.000
-0.080
-1.96%
After Hours: 4.110 +0.11 +2.75% 18:50 04/26 EDT
OPEN
4.090
PREV CLOSE
4.080
HIGH
4.145
LOW
3.990
VOLUME
2.75M
TURNOVER
0
52 WEEK HIGH
7.45
52 WEEK LOW
1.610
MARKET CAP
1.06B
P/E (TTM)
-3.3389
1D
5D
1M
3M
1Y
5Y
Amgen’s Blincyto data send Cullinan higher
Cullinan Therapeutics added ~58% last week after peer-reviewed data for Amgen's leukemia therapy, Blincyto. The drug targets CD19 surface antigens on B cells similar to CGEM's lymphoma candidate. The company's stock rose 31% on Friday after Nature Medicine published the data.
Seeking Alpha · 13h ago
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 2d ago
Autolus Therapeutics Announces Abstract For Longer-Term Follow-Up And Additional Data Analysis Of Pivotal Phase 2 FELIX Study Of obe-cel For Adult r/r B-ALL Selected For An Oral Presentation At ASCO
Autolus Therapeutics plc's obecabtagene autoleucel selected for oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago. The company is developing next-generation programmed T cell therapies. The study of the drug in relapsed/refractory B-cell acute lymphoblastic leukemia was selected for an oral presentation.
Benzinga · 3d ago
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Autolus Therapeutics plc will release its first quarter 2024 financial results and operational highlights before open of US markets on Tuesday, May 14, 2024. The company is developing next-generation programmed T cell therapies. Autolus is a clinical-stage biopharmaceutical company.
Barchart · 5d ago
Weekly Report: what happened at AUTL last week (0415-0419)?
Weekly Report · 6d ago
Recent 9.9% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 165% over 1 year
Autolus Therapeutics plc's share price has dropped 23% in the last month. The company has shed US$141m from its market cap. The share price is up an impressive 165% over the last year. The business has no meaningful revenue or profit, but shareholders are speculating on growth. AutolusTherapeutics is showing 3 warning signs in our analysis.
Simply Wall St · 04/19 16:40
Weekly Report: what happened at AUTL last week (0408-0412)?
Weekly Report · 04/15 09:11
Buy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive Outlook
Needham maintained a Buy rating on Autolus Therapeutics (AUTL) with a price target of $9.00. Gil Blum has given his Buy rating due to a combination of factors surrounding the potential of the company. The company’s focus on engineering precise, controllable, tailored T-cell therapies may address significant unmet needs in the treatment of cancer.
TipRanks · 04/12 10:06
More
About AUTL
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Webull offers Autolus Therapeutics PLC (ADR) stock information, including NASDAQ: AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.